uniQure hemophilia therapy hits co-primary Phase III endpointuniQure N.V. (NASDAQ:QURE) said gene therapy etranacogene dezaparvovec met one primary endpoint of the Phase III HOPE-B trial to treat hemophilia B. The adeno-associated viral serotype 5 (AAV5)...

The first interim Phase III readout for Sputnik V suggests the Russian COVID-19 vaccine and BNT162b2 from BioNTech and Pfizer have similar efficacies as an interim analysis that will reveal whether Moderna...

The outpatient setting of the first clinical trial of Vir and GSK’s lead antiviral COVID-19 mAb buffers the study from being affected by FDA’s emergency use authorization for convalescent plasma. The partners also differentiated their...

The academic team behind the only AAV vaccine candidate for COVID-19 thinks its vector can get the best of both worlds and induce stronger antibody responses than adenoviral vaccines, while still activating T cells. Moreover,...

As the number of vaccines in development for COVID-19 climbs past 110, more modalities are starting to be represented in the clinic. As of last week, the COVID-19 vaccine modalities in the clinic were inactivated...

With an eye towards a functional cure for chronic HBV, Vir plans to begin testing its siRNA therapy next half in combination with immune boosters. Phase I/II data unveiled Wednesday showed that VIR-2218 alone led...

More than a dozen biopharmas Thursday announced delays or disruptions to clinical programs and regulatory timelines as companies begin to turn their attention to managing their trials through the COVID-19 crisis. The setbacks came as...

By combining TCR-antigen matching company Cogen with T cell therapy play Torque, Flagship Pioneering’s Repertoire Immune Medicines Inc. aims to boost the latter’s ongoing oncology programs while demonstrating clinical proof of concept for the former’s...

The tepid performances of two high-profile IPOs late in the week added to a widening body of evidence that investors’ demand for new biotech listings has begun to weaken, despite a long queue of companies...

Although more than half of the $630.7 million in equity funding that Vir Biotechnology has raised remains unspent, the immunology and infectious disease company -- led by former Biogen and Exelixis CEO George Scangos --...